Aduro Biotech, Inc. (NASDAQ:ADRO) COO Gregory W. Schafer sold 40,000 shares of the stock in a transaction that occurred on Wednesday, June 28th. The stock was sold at an average price of $11.26, for a total value of $450,400.00. Following the transaction, the chief operating officer now owns 160,979 shares in the company, valued at approximately $1,812,623.54. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Shares of Aduro Biotech, Inc. (ADRO) traded down 1.13% during midday trading on Friday, hitting $13.10. The company’s stock had a trading volume of 370,422 shares. Aduro Biotech, Inc. has a 52-week low of $8.75 and a 52-week high of $16.43. The firm’s market cap is $915.86 million. The stock’s 50 day moving average is $12.03 and its 200-day moving average is $10.94.
Aduro Biotech (NASDAQ:ADRO) last released its quarterly earnings results on Tuesday, May 2nd. The biotechnology company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.07. The firm had revenue of $3.77 million during the quarter, compared to analyst estimates of $3.74 million. Aduro Biotech had a negative net margin of 166.85% and a negative return on equity of 35.35%. Equities analysts predict that Aduro Biotech, Inc. will post ($1.41) EPS for the current fiscal year.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in ADRO. Bank of New York Mellon Corp raised its position in Aduro Biotech by 3.8% in the first quarter. Bank of New York Mellon Corp now owns 148,166 shares of the biotechnology company’s stock worth $1,593,000 after buying an additional 5,470 shares during the period. Quantitative Systematic Strategies LLC bought a new position in shares of Aduro Biotech during the first quarter valued at about $145,000. Fox Run Management L.L.C. bought a new position in shares of Aduro Biotech during the first quarter valued at about $202,000. Daiwa SB Investments Ltd. bought a new position in shares of Aduro Biotech during the first quarter valued at about $153,000. Finally, Creative Planning raised its position in shares of Aduro Biotech by 73.9% in the first quarter. Creative Planning now owns 15,000 shares of the biotechnology company’s stock valued at $161,000 after buying an additional 6,375 shares during the period. Hedge funds and other institutional investors own 35.65% of the company’s stock.
A number of equities research analysts recently issued reports on ADRO shares. BidaskClub raised Aduro Biotech from a “hold” rating to a “buy” rating in a research report on Tuesday. Zacks Investment Research raised Aduro Biotech from a “hold” rating to a “buy” rating and set a $13.00 price target on the stock in a research report on Tuesday, July 4th. Rodman & Renshaw started coverage on Aduro Biotech in a research report on Monday, May 1st. They set a “buy” rating and a $18.00 price target on the stock. Cowen and Company started coverage on Aduro Biotech in a research report on Tuesday, July 18th. They set an “outperform” rating on the stock. Finally, HC Wainwright started coverage on Aduro Biotech in a research report on Monday, May 1st. They set a “buy” rating and a $18.00 price target on the stock. Nine investment analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and a consensus target price of $19.00.
About Aduro Biotech
Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.
Receive News & Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.